Michelle Turner, PharmD; G. Ralph Corey, MD; Elias Abrutyn, MD
Potential Financial Conflicts of Interest: Employment: G.R. Corey (Duke University Medical Center); Consultancies: G.R. Corey (Cubist).
Requests for Single Reprints: Michelle Turner, PharmD, Duke University Medical Center, Box 3089, Durham, NC 27710.
Current Author Addresses: Dr. Turner: Duke University Medical Center, Box 3089, Durham, NC 27710.
Dr. Corey: Duke Clinical Research Institute, 2400 Pratt Street, Room 7030Durham, NC 27710.
Dr. Abrutyn: Drexel University College of Medicine, Mailstop 441, 245 North 15th Street, Philadelphia, PA 19102-1192.
Turner M., Corey G., Abrutyn E.; Telithromycin. Ann Intern Med. 2006;144:447-448. doi: 10.7326/0003-4819-144-6-200603210-00014
Download citation file:
Published: Ann Intern Med. 2006;144(6):447-448.
Elsewhere in this issue, Clay and colleagues (1) describe a serious adverse event related to telithromycin. This report should cause physicians who prescribe telithromycin to pause in order to be sure it is the right antibiotic for the circumstances. Herein we provide information about telithromycin to help clinicians decide when to prescribe it.
Telithromycin (Ketek, Aventis Pharmaceuticals, Bridgewater, New Jersey), the first marketed ketolide antibiotic, is a modification of the macrolide structure. Like macrolides (2), telithromycin blocks protein synthesis (3). However, compared with macrolides, it has increased affinity for the binding sites on domains II and V of the 50S ribosomal subunit (4). This attribute provides increased activity against bacteria that are resistant to macrolides because of both methylation- and efflux pump–mediated mechanisms (ermB and mefA, respectively) (2). Telithromycin is active in vitro against bacterial pathogens most commonly isolated from patients with mild to moderate community-acquired respiratory tract infections. These include infection with Streptococcus pneumoniae (both penicillin- and macrolide-resistant strains) as well as ß-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis(5, 6). Telithromycin is also active in vitro against Mycoplasma pneumoniae and Chlamydophilia pneumoniae(7). While telithromycin demonstrates potent in vitro activity against other respiratory pathogens (such as Legionella pneumophila and Bordetella pertussis), clinical data about its effectiveness for these infections is limited. It is not active against erythromycin-resistant Staphylococcus aureus(2).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Infectious Disease, Liver Disease, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only